Atea Historical Cash Flow
| AVIR Stock | USD 3.37 0.12 3.69% |
Analysis of Atea Pharmaceuticals cash flow over time is an excellent tool to project Atea Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 26.4 M or Change In Working Capital of 17 M as it is a great indicator of Atea Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Atea Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atea Pharmaceuticals is a good buy for the upcoming year.
Atea |
About Atea Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Atea balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Atea's non-liquid assets can be easily converted into cash.
Atea Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Atea Pharmaceuticals value has been used up. For tax purposes Atea Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Atea Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most accounts from Atea Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Atea Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.At this time, Atea Pharmaceuticals' Investments are relatively stable compared to the past year. As of 11/24/2024, Change In Working Capital is likely to grow to about 17 M, while Stock Based Compensation is likely to drop slightly above 26.4 M.
| 2010 | 2023 | 2024 (projected) | Change To Inventory | 5.1M | 4.6M | 4.1M | Sale Purchase Of Stock | 531.7M | 1.3M | 1.3M |
Atea Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Atea Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atea Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (2K) | (26K) | (4K) | (455.4M) | 40.3M | 42.3M | |
| Change In Cash | (12.8M) | 828.5M | (85.5M) | (576.0M) | (44.8M) | (42.6M) | |
| Stock Based Compensation | 624K | 7.5M | 39.6M | 46.7M | 49.4M | 26.4M | |
| Free Cash Flow | (12.8M) | 296.7M | (87.0M) | (122.9M) | (85.4M) | (81.1M) | |
| Change In Working Capital | 579K | 300.2M | (247.8M) | (46.6M) | 16.2M | 17.0M | |
| Begin Period Cash Flow | 34.6M | 21.8M | 850.2M | 764.7M | 188.7M | 343.7M | |
| Total Cashflows From Investing Activities | (2K) | (26K) | (4K) | (455.4M) | (409.9M) | (389.4M) | |
| Other Cashflows From Financing Activities | (15K) | 214.1M | (4K) | 140K | 257K | 244.2K | |
| Other Non Cash Items | 501K | 13.8M | 29.4M | (5.5M) | 33.1M | 34.8M | |
| Total Cash From Operating Activities | (12.8M) | 296.7M | (87.0M) | (121.0M) | (85.4M) | (81.1M) | |
| Change To Operating Activities | 407K | 5.1M | 43.2M | (44.6M) | (40.1M) | (38.1M) | |
| Issuance Of Capital Stock | 106.6M | 531.7M | 1.5M | 230K | 207K | 196.7K | |
| Net Income | (14.0M) | (10.9M) | 121.2M | (115.9M) | (136.0M) | (129.2M) | |
| Total Cash From Financing Activities | (15K) | 531.7M | 1.5M | 370K | 257K | 244.2K | |
| End Period Cash Flow | 21.8M | 850.2M | 764.7M | 188.7M | 143.8M | 136.6M | |
| Change To Netincome | 624K | 7.5M | 39.6M | 41.3M | 47.4M | 49.8M | |
| Change To Liabilities | 157K | 300.9M | (291.1M) | (2.0M) | (1.8M) | (1.7M) |
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
Moving against Atea Stock
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.62 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.61 | GILD | Gilead Sciences | PairCorr |
| 0.48 | KZR | Kezar Life Sciences | PairCorr |
| 0.45 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.